FDA committees say keep rosiglitazone available but increase warnings.
Tanne
Janice Hopkins
JH
D017277:Drug Approval; D004348:Drug Labeling; D006801:Humans; D007004:Hypoglycemic Agents / Q000600:supply & distribution*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000600:supply & distribution*; D014481:United States; D014486:United States Food and Drug Administration
D007004:Hypoglycemic Agents; D045162:Thiazolidinediones; D000077154:Rosiglitazone